Childhood/adulthood adiposity · women with type 2 diabetes
1 finding from 1 review
Childhood/adulthood diabetes · women with type 2 diabetes
1 finding from 1 review
Large‐for‐gestational age · women with type 2 diabetes
It is very uncertain whether infant outcomes: oral anti‐diabetic agent (metformin) changes large‐for‐gestational age compared with insulin (very low certainty).
1 finding from 1 review
Perinatal mortality · women with type 2 diabetes
1 finding from 1 review
Hypertensive disorders of pregnancy: pre‐eclampsia · women with type 2 diabetes
It is very uncertain whether maternal outcomes: oral anti‐diabetic agent (metformin) changes hypertensive disorders of pregnancy: pre‐eclampsia compared with insulin (very low certainty).
1 finding from 1 review
Hypertensive disorders of pregnancy (pregnancy‐induced hypertension) · women with type 2 diabetes
Maternal outcomes: oral anti‐diabetic agent (metformin) may leads to lower hypertensive disorders of pregnancy: pregnancy‐induced hypertension compared with insulin (low certainty).
1 finding from 1 review
Caesarean section · women with type 2 diabetes
Maternal outcomes: oral anti‐diabetic agent (metformin) may leads to lower caesarean section compared with insulin (low certainty).
1 finding from 1 review
Induction of labour · women with type 2 diabetes
It is very uncertain whether maternal outcomes: oral anti‐diabetic agent (metformin) changes induction of labour compared with insulin (very low certainty).
1 finding from 1 review
Perineal trauma · women with type 2 diabetes
1 finding from 1 review
Postnatal depression · women with type 2 diabetes
1 finding from 1 review
Postnatal weight retention · women with type 2 diabetes
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (moderate certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Number of participants experiencing an attacka · people with familial Mediterranean fever
Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).
1 finding from 1 review
Duration of attackse,f · people with familial Mediterranean fever
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Time between attacks · people with familial Mediterranean fever
1 finding from 1 review
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with familial Mediterranean fever
It is very uncertain whether colchicine (oral) changes adverse drug reactions compared with placebo (very low certainty).
1 finding from 1 review